StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) company profile

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)

Close on Nov 18, 2026Market cap $62.83KP/E –Yield –

About Addex Therapeutics

Pharmaceutical Preparations, SIC 2834

Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company focused on discovering and developing orally available small molecule drug candidates. The company specializes in allosteric modulators targeting G-protein coupled receptors to treat conditions with high unmet medical needs. Its proprietary development pipeline includes dipraglurant for brain injury and post-stroke sensorimotor recovery, ADX71149 for evaluated neurological indications, and positive allosteric modulator programs targeting chronic cough and substance use disorders. Rather than selling directly to commercial consumers, the company advances candidates through internal programs or licenses them to pharmaceutical partners, such as Indivior.

The company operates internationally with its corporate headquarters and principal executive offices located in Geneva, Switzerland, alongside an additional investor contact office in the United States. Its operations include proprietary clinical and preclinical development programs supported by patent portfolios covering the United States, Europe, and Japan.

Summary of the business section of Addex Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Addex Therapeutics Ltd.
Founded
2002
Headquarters
Geneva, V8
Address
Chemin Des Mines 9 CH-1202
Phone
01141228841555
Employees
3, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
V8
Fiscal year ends
December 31
Auditor
BDO AG, Zurich, Switzerland

Stock & identifiers

Ticker
ADXN
Exchange
Nasdaq
IPO date
Jan 28, 2020
Shares outstanding
148M, Dec 31, 2025
Filer category
Non-accelerated filer
Stock splits
1-for-20 reverse, Oct 23, 2023
SEC CIK
1574232
CUSIP
00654J206
ISIN
US00654J2069
FIGI
BBG00R48ST95
Share class FIGI
BBG00R48SV18
LEI
89450068Y9KVP2MQGH86
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Timothy Mark DyerCHIEF EXECUTIVE OFFICER, Director435,192
Roger MillsCHIEF MEDICAL OFFICER, Director785,976
Lenaic Nathanael TeyssedouPRINCIPAL ACCOUNTING OFFICER–
Mikhail KalinichevHEAD OF TRANSLATIONAL SCIENCE0
Vincent Michael LawtonDirector2,507,987
Raymond George HillDirector0
Jason Raleigh NunnDirector219,561
Isaac MankeDirector219,561

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 28, 2020
Securities offered
11,553,190
Exchange
Nasdaq
First trading day
Jan 29, 2020
First-day close
$14.50
Lock-up ends (est.)
Jul 27, 2020

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We had 3 full-time employees as of December 31, 2025 compared to 2 at December 31, 2024.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?